Angiopoietin-1 and Tie2-Based Dual Cell Therapy Enhances Antiangiogenic Barrier Function in a Retina-Mimetic Model for Neovascular Retinal Disease
- PMID: 40690116
- PMCID: PMC12297198
- DOI: 10.1007/s13770-025-00739-4
Angiopoietin-1 and Tie2-Based Dual Cell Therapy Enhances Antiangiogenic Barrier Function in a Retina-Mimetic Model for Neovascular Retinal Disease
Abstract
Background: Choroidal neovascularization (CNV) is a major pathological process underlying retinal degenerative diseases such as wet age-related macular degeneration. While anti-VEGF therapies are widely used, limitations in response and vascular instability necessitate new approaches that promote both antiangiogenic effects and barrier restoration.
Methods: A dual-cell therapy strategy was developed using human umbilical vein endothelial cells (HUVECs) genetically modified to overexpress Tie2 and mesenchymal stem cells (MSCs) engineered to secrete Angiopoietin-1 (Ang1). Antiangiogenic efficacy was evaluated using scratch assays, Transwell migration, and tube formation under VEGF stimulation. A retina-mimetic 2.5D co-culture system incorporating iPSC-derived RPE cells and mCherry-labeled ECs was used to assess endothelial invasion and epithelial barrier preservation.
Results: Tie2/Ang1-modified cells significantly suppressed angiogenic behavior. Transwell migration showed OD595 crystal violet absorbance decreased from 3.54 ± 0.27 (control HUVEC) to 1.28 ± 0.08 (Tie2 overexpressed HUVEC in MSC Ang1 conditioned medium) under VEGF stimulation (p < 0.01). Tube formation area cultured in VEGF dropped from 1.25 ± 0.05 in control group to 0.74 ± 0.07 in Tie2 overexpressed group cultured with MSC-Ang1 conditioned medium (p < 0.01). In the retina-mimetic model, EC infiltration to the RPE monolayer across Transwell membrane decreased from 52.2 ± 8.5% in control HUVEC to 5.6 ± 4.3% with HUVEC-Tie2 + Ang1 conditioned medium under VEGF (p < 0.001).
Conclusion: This study demonstrates that co-delivery of Ang1 and Tie2 via engineered ECs and MSCs synergistically inhibits VEGF-induced angiogenesis and choroidal migration while protecting epithelial barrier function. The retina-mimetic co-culture platform further validates the translational relevance of this dual-cell approach as a regenerative and antiangiogenic strategy in retinal vascular disease.
Keywords: Angiogenesis; Angiopoietin-1; Barrier restoration; Cell therapy; Retina-mimetic model; Tie2.
© 2025. Korean Tissue Engineering and Regenerative Medicine Society.
Conflict of interest statement
Declarations. Ethical approval: There are no animal experiments carried out for this article. Conflict of interest: The authors declare no conflicts of interest related to this manuscript.
Similar articles
-
Activation of angiopoietin-1 signaling with engineering mesenchymal stem cells promoted efficient angiogenesis in diabetic wound healing.Stem Cell Res Ther. 2025 Feb 21;16(1):75. doi: 10.1186/s13287-025-04207-7. Stem Cell Res Ther. 2025. PMID: 39985096 Free PMC article.
-
Exosomal SPRY4 from adipogenic BMSCs impairs angiogenesis via the PTPRB/TIE2/PI3K axis in Steroid-induced osteonecrosis of the femoral head.Stem Cell Res Ther. 2025 Jul 15;16(1):375. doi: 10.1186/s13287-025-04505-0. Stem Cell Res Ther. 2025. PMID: 40660390 Free PMC article.
-
Angiopoietin1/Tie2 and VEGF/Flk1 induced by MSC treatment amplifies angiogenesis and vascular stabilization after stroke.J Cereb Blood Flow Metab. 2007 Oct;27(10):1684-91. doi: 10.1038/sj.jcbfm.9600475. Epub 2007 Mar 14. J Cereb Blood Flow Metab. 2007. PMID: 17356562 Free PMC article.
-
Anti-vascular endothelial growth factor biosimilars for neovascular age-related macular degeneration.Cochrane Database Syst Rev. 2024 Jun 3;6(6):CD015804. doi: 10.1002/14651858.CD015804.pub2. Cochrane Database Syst Rev. 2024. PMID: 38829176 Free PMC article.
-
Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia.Cochrane Database Syst Rev. 2016 Dec 15;12(12):CD011160. doi: 10.1002/14651858.CD011160.pub2. Cochrane Database Syst Rev. 2016. PMID: 27977064 Free PMC article.
References
-
- Heier JS, Lad EM, Holz FG, Rosenfeld PJ, Guymer RH, Boyer D, et al. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet. 2023;402:1434–48. - PubMed
-
- Wang Z, Zhang Y, Xu C, Peng A, Qin H, Yao K. Advancements in age-related macular degeneration treatment: From traditional anti-VEGF to emerging therapies in gene, stem cell, and nanotechnology. Biochem Pharmacol. 2025;236:116902. - PubMed
-
- Green KR, Beazley-Long N, Lynch AP, Allen CL, Bates DO, Benest AV. Quantification of angiogenesis in laser choroidal neovascularization. Methods Mol Biol. 2022;2441:223–31. - PubMed
-
- Kumar A, Ferro Desideri L, Ting MYL, Anguita R. Perspectives on the currently available pharmacotherapy for wet macular degeneration. Expert Opin Pharmacother. 2024;25:755–67. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical
Miscellaneous